3 Reasons Momentum Stock Investors Will Love Argos Therapeutics (ARGS)
Many investors like to look for momentum in stocks, but this can be very tough to define. There is great debate regarding which metrics are the best to focus on in this regard, and which are not really quality indicators of future performance. Fortunately, with our new style score system we have identified the key statistics to pay close attention to and thus which stocks might be the best for momentum investors in the near term.
This method discovered several great candidates for momentum-oriented investors, but today let’s focus in on Argos Therapeutics, Inc. ARGS as this stock is looking especially impressive right now. And while there are numerous ways in which this company could be a great choice, we have highlighted three of the most vital reasons for ARGS’s status as a solid momentum stock below:
Short Term Price Change for Argos Therapeutics
A great place to look for finding momentum stocks is by inspecting short term price activity. This can help to reflect the current interest in a stock and if buyers or sellers have the upper hand right now. It is especially useful to compare it to the industry as this can help investors pinpoint the top companies in a particular area.
With a one week price change of nearly 0.32% compared to an industry average of a negative 0.04%, ARGS is certainly well-positioned in this regard. The stock is also looking quite well from a longer time frame too, as the four week price change compares favorably with the industry at large as well.
Fiscal Year EPS Estimate Change for ARGS
In addition to price performance, it is also important to take a look at earnings estimate changes for the full year. This can show if ARGS is poised to make a run based on fundamentals, or if the company is simply moving on speculation.
Over the past month, the full year earnings estimate for ARGS has risen by roughly 6%. On its own this is impressive, but consider that it also beats the industry average of 0.00% too. The trend is undeniably in Argos Therapeutics’ favor right now, and it suggests that the momentum might be long lasting for this stock.
ARGS Earnings Estimate Revisions Moving in the Right Direction
While the great momentum factors outlined in the preceding paragraphs might be enough for some investors, we should also take into account broad earnings estimate revision trends. A nice path here can really help to show us a promising stock, and we have actually been seeing that with ARGS as of late too.
Over the past month, 1 earnings estimate have gone higher compared to 0 lower for the full year, while we are also seeing 1 upward revisions versus 0 downward revisions for the next year time frame too. These revisions have helped to boost the consensus estimate as a month ago ARGS was expected to post a loss of $3.62 per share for the full year, though today it looks to post a loss of $3.58 for the full year now, representing a solid increase which is something that should definitely be welcomed news to would-be investors.
Bottom Line
Given these factors, investors shouldn’t be surprised to note that we have ARGS as a security with a Zacks Rank #2 (Buy) and a Momentum Score of ‘B’. So if you are looking for a fresh pick that has potential to move in the right direction, definitely keep ARGS on your short list as this looks be a stock that is very well-positioned to soar in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ARGOS THERAPEUT (ARGS): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
